

1 **The founder missense mutation of *WFDC2* in Koreans leads to severe respiratory**
2 **distress accompanied by bronchiectasis and rhinosinusitis**

3

4 Jae Won Roh,^{1,2,8} Jiyoung Oh,^{3,8} Se Jin Kim,^{1,2,8} Ji Won Hong,^{1,2,8} Jiyeon Ohk,⁴ Hyo Sup
5 Shim,⁵ Hyung-Ju Cho,⁶ Ala Woo,⁷ Song Yee Kim,⁷ Young Ae Kang,⁷ Hosung Jung,⁴ Kyung
6 Won Kim,^{3,*} Moo Suk Park,^{7,*} Heon Yung Gee^{1,2,*}

7

8 ¹Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project,
9 Yonsei University College of Medicine, Seoul 03722, Republic of Korea

10 ²Woo Choo Lee Institute for Precision Drug Development, Seoul 03722, Republic of Korea

11 ³Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul
12 03722, Republic of Korea

13 ⁴Department of Anatomy, Graduate School of Medical Science, Brain Korea 21 Project,
14 Yonsei University College of Medicine, Seoul 03722, Republic of Korea

15 ⁵Department of Pathology, Yonsei University College of Medicine, Seoul, Korea

16 ⁶Department of Otorhinolaryngology, The Airway Mucus Institute, Korea Mouse
17 Phenotyping Center (KMPC), Taste Research Center, Yonsei University College of Medicine,
18 Seoul 03722, Republic of Korea

19 ⁷Department of Internal Medicine, Severance Hospital, Yonsei University College of
20 Medicine, Seoul 03722, Republic of Korea

21 ⁸These authors contributed equally

22 *Correspondence:

23 Kyung Won Kim

24 Department of Pediatrics, Yonsei University College of Medicine, 50-1 Yonsei-Ro,

25 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-2050; email: kwkim@yuhs.ac

26

27 Moo Suk Park

28 Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-Ro,

29 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-1955; email: pms70@yuhs.ac

30

31 Heon Yung Gee

32 Department of Pharmacology, Yonsei University College of Medicine, 50-1 Yonsei-Ro,

33 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-8755; email: HYGEE@yuhs.ac

34 **ABSTRACT**

35 **Background**

36 Chronic airway diseases like cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) pose
37 substantial clinical challenges. This study explores the p.C97W variant in *WFDC2*, proposed
38 as a new genetic origin of respiratory distress, especially among Koreans.

39 **Methods**

40 Whole-exome/genome sequencing (WES/WGS) were performed on 64 patients from 62
41 families presenting with severe bronchiectasis and chronic rhinosinusitis. *In vitro* analyses
42 and protein modeling were utilized to evaluate the functional implications of the *WFDC2*
43 variant.

44 **Results**

45 Pathogenic variants were found in 11.3% of families, including a novel homozygous *WFDC2*
46 missense variant (c.291C>G, p.Cys97Trp) in five unrelated families, confirmed by Sanger
47 sequencing. The variant, rare globally but more frequent in Koreans, caused persistent wet
48 cough, chronic rhinosinusitis, and bronchiectasis in affected patients. Lung tissue pathology
49 showed chronic inflammation and interstitial fibrosis. The p.C97W variant impaired *WFDC2*
50 protein folding, secretion, and function.

51 **Conclusions**

52 The p.C97W variant in *WFDC2* is a critical genetic factor in severe chronic airway disease
53 that shares clinical features with CF and PCD. Given its implications for diagnosis and
54 treatment, genetic testing for *WFDC2* mutations in individuals with CF or PCD-like
55 symptoms is recommended.

56 **INTRODUCTION**

57 In humans, the respiratory epithelium is critical for air transport, mucociliary clearance, and
58 immune regulation. The airway epithelium comprises various cell types, including basal,
59 ciliated, goblet, and club cells, as well as rare types like tuft cells, ionocytes, and
60 neuroendocrine cells.¹ The mucosal surface of the respiratory tract contributes to innate
61 immune defense. Each epithelial cell type plays a distinct role in maintaining airway integrity
62 and the mucociliary clearance system, by producing antioxidants, protease inhibitors,
63 antimicrobial peptides, or by secreting mucins and surfactants.^{2,3} Dysregulation of these
64 processes due to genetic or environmental factors can lead to the pathophysiology of severe
65 viral infections and chronic pulmonary disorders, including asthma,^{1,4,5} cystic fibrosis
66 (CF),^{1,6-8} and primary ciliary dyskinesia (PCD).^{1,9,10}

67 In this study, we identified a homozygous missense variant (c.291C>G, p.C97W) in
68 *WFDC2*, a serine/threonine protease inhibitor with anti-bacterial activity, through whole-
69 exome and genome sequencing in families affected by respiratory conditions resembling
70 PCD. Individuals with this variant exhibited chronic inflammation, bronchiectasis, interstitial
71 fibrosis, and infections caused by *Pseudomonas aeruginosa*. Due to its implications for
72 diagnosis and treatment, genetic testing for *WFDC2* mutations is recommended for
73 individuals with CF or PCD-like symptoms.

74 **RESULTS**

75 **Identification of the *WFDC2* variant**

76 The WES or WGS analysis pipeline to identify the potential genetic causes in patients with
77 severe bronchiectasis and chronic rhinosinusitis (n = 64 from 62 families) is shown in Fig. S1.
78 Pathogenic variants were identified in 7 of the 62 families (11.3%): five with variants in
79 PCD-linked genes (six patients) and two (two patients) with *CFTR* variants (Fig. 1A, B).
80 Furthermore, a homozygous missense variant (c.291C>G, p.Cys97Trp) in *WFDC2* was
81 identified in five unrelated families (Fig. 1C, and Fig. S2). Sanger sequencing confirmed this
82 homozygous mutation in affected probands and their siblings, while the unaffected mother
83 was heterozygous (Fig. 1D). The allele frequency of this variant was 0.00001611 in the
84 global population 0.0004051 in East Asians, and 0.0018 in the Korean population, as reported
85 in the Genome Aggregation Database (gnomAD; Table S1). Haplotype analysis revealed that
86 individuals carrying the c.291C>G *WFDC2* mutation shared a genomic region of
87 approximately 138.5 kb surrounding the variant (Table S2). Subsequent haplotype analysis
88 using the LDhap Tool¹¹ using eight selected SNPs within the shared region revealed that
89 individuals with the c.291C>G *WFDC2* mutation share a rare H4 haplotype, with a frequency
90 of 0.63% in the homozygous state (Table S2). This finding suggests this variant as a founder
91 allele.

92

93 **Clinical phenotypes of individuals with the *WFDC2* variant**

94 All six patients from five unrelated families presented with persistent wet cough and chronic
95 rhinosinusitis (Fig. 2C). Chest CT scans revealed bronchiectasis in five patients, while one
96 patient (P1946-21) declined the scan (Fig. 2A). Pathological examination of the original lung
97 tissue from three female patients (P1969-21, P2678-21, and P2783-21) who underwent lung

98 transplantation at an average age of 33 years (range: 21–41 years; Table 1) revealed chronic
99 inflammation, bronchiectasis, and interstitial fibrosis (Fig. 2D). All patients had *P. aeruginosa*
100 lung infections, and pulmonary function demonstrated a severe airflow obstruction pattern
101 before lung transplantation. Two siblings (P5-21 and P5-22) of three male patients recently
102 visited our hospital, both presenting with bronchiectasis and reduced FEV1% predicted (Fig.
103 2B, and Table 1).

104 The average age at the onset of respiratory symptoms was 7.8 years (range, 1 month
105 to 13 years). Initial clinical diagnoses based on respiratory symptoms included neonatal
106 pneumonia in patients P1946-21 and P1969-21; bronchiectasis in patients P2678-21, P2783-
107 21, P5-21, and P5-22; and chronic rhinosinusitis in patients P5-21 and P5-22. Bronchiectasis
108 was confirmed during childhood in two-thirds of the patients, with one patient diagnosed at
109 late 0's (P2678-21) and three patients diagnosed at early 10's (P2783-21, P5-21, and P5-22).
110 The three patients who underwent lung transplants (P1969-21, P2678-21, and P2783-21)
111 have maintained stable lung structure and function for two, seven, and fourteen years,
112 respectively (Fig. 2, and Table 1).

113

114 **Effect of p.C97W variant on WFDC2 function**

115 As shown in Fig. 3A, WFDC2 contains a N-terminal signal peptide that is involved in
116 trafficking and secretion, and two whey acidic protein (WAP) domains connected by a short
117 loop. Each WAP domain includes eight cysteine residues that form four disulfide bonds.
118 Structure prediction using AlphaFold2¹² showed that C97 located in the second WAP domain
119 forms a disulfide bond with C109 (Fig. 3A). Multiple sequence alignments of human
120 WFDC2 with its orthologs from several vertebrate species demonstrated that both C97 and
121 C109 are highly conserved across vertebrates (Fig. 3B). Additionally, the *in silico* prediction

122 scores classified the C97W variant as pathogenic or disease-causing (Table S1).

123 Next, we predicted the structures of both the wild-type (WT) and p.C97W mutant
124 *WFDC2* using ColabFold¹³ and AlphaFold2.¹² The p.C97W mutant failed to form a disulfide
125 bond with C109, in contrast to WT (Fig. 3C). Additionally, the bulky side chain of the Trp
126 (W) residue disrupted hydrogen bond formation near W97 in the second WAP domain (Fig.
127 3C). *WFDC2* forms dimeric structures;¹⁴ therefore, we predicted the dimeric structures of WT
128 and p.C97W. Clustering of the structures from multiple AlphaFold2 runs showed that the
129 p.C97W structure predominantly exists in a 'trans-trans' configuration, where the second
130 WAP domain is untangled and interacts with the other subunit. In contrast, the WT *WFDC2*
131 dimers were more likely to exist in the 'cis' configuration (Fig. 3C, and Fig. S3).

132 Assessment of the effects of the p.C97W mutant on *WFDC2* secretion in human
133 embryonic kidney (HEK293T) cells overexpressing WT or p.C97W *WFDC2* revealed that
134 WT *WFDC2* produced a single band of approximately 24 kDa in both the lysate and culture
135 media. In contrast, the p.C97W variant was not secreted and showed reduced expression in
136 the lysate (Fig. 3D). Immunofluorescence analysis in HEK293T cells showed colocalization
137 of both WT and p.C97W *WFDC2* with the endoplasmic reticulum marker, suggesting no
138 defect in intracellular localization (Fig. S4A). Furthermore, treatment with tunicamycin, an
139 inhibitor of N-linked glycosylation, or glycosidase digestion by incubation of cell lysates
140 with glycosidases, such as PNGase F or Endo H, demonstrated that both WT and p.C97W
141 were glycosylated (Fig. S4B, C), as indicated by the shift in band molecular weight with
142 no difference between the WT and mutant (Fig. S4B, C). This finding indicated that
143 *WFDC2* was glycosylated, as previously described.¹⁴ In summary, these findings indicated
144 that the p.C97W mutation disrupts *WFDC2* protein folding and secretion, impairing its
145 function.

146 **DISCUSSION**

147 In this study, we identified a novel *WFDC2* mutation (c.291C>G; p.C97W) as the causative
148 factor in severe lung disease. This autosomal recessive variant leads to chronic inflammation,
149 bronchiectasis, interstitial fibrosis, and severe airflow obstruction, often necessitating lung
150 transplantation. Population data from gnomAD and KRGDB indicate that this allele has a
151 relatively high frequency in East Asian populations, particularly in the Korean population.
152 Based on these data, approximately three out of one million individuals are homozygous for
153 this mutation, suggesting that around 150 individuals in South Korea could be affected. In
154 contrast, the previously reported c.145T>C; p.C49R variant, identified as a European founder
155 allele, is extremely rare in East Asian populations, including Koreans. However, it has a
156 higher frequency in the European population with an allele frequency of 0.0001814,
157 equivalent to three individuals per ten million and approximately 2,239 patients in Europe.
158 Additionally, 22 loss-of-function (LoF) alleles in *WFDC2* have been reported in gnomAD,
159 with a combined homozygous frequency of approximately 0.000000003178.

160 Respiratory phenotypes of *WFDC2* deficiency identified in our study and another
161 study¹⁵ present with clinical features that closely resemble CF and PCD, with symptoms
162 including bronchiectasis, chronic rhinosinusitis, and recurrent respiratory infections. Like CF,
163 patients with *WFDC2* mutations develop bronchiectasis across all lung lobes and are prone to
164 chronic *P. aeruginosa* infections, indicating a more severe and diffuse impact on lung
165 structure in *WFDC2* deficiency and CF compared to PCD. Furthermore, nasal and sinus
166 abnormalities, including chronic rhinosinusitis and nasal polyps, are prevalent across all three
167 conditions. In this study, three patients with *WFDC2* mutations underwent lung
168 transplantation due to respiratory failure, further highlighting the severe progression of the
169 disease.

170 The *WFDC2* c.291C>G; p.C97W variant shares molecular similarities with the
171 previously described c.145T>C; p.C49R variant.¹⁵ Both are autosomal recessive missense
172 mutations in cysteine residues within the WAP domain, a critical region for disulfide bond
173 formation, and lead to LoF by disrupting the WAP domain. The key difference between the
174 two variants is that the p.C49R variant affects the first WAP domain, while the p.C97W
175 variant affects the second. Additionally, unlike the p.C49R variant, which is associated with
176 glycosylation defects,¹⁵ our data did not reveal glycosylation differences for the p.C97W
177 variant, nor did it alter intracellular localization compared to the WT protein. Structural
178 modeling using AlphaFold2,¹² aligns well with the disruption of WAP domain integrity due to
179 the loss of disulfide bonds, suggesting that improper dimer formation might explain the
180 differences in the effects of the p.C97W variant. Despite these structural differences, both
181 variants exhibit similar defects in protein secretion, suggesting comparable pathological
182 consequences in humans.

183 In conclusion, we identified the p.C97W *WFDC2* variant as a novel cause of severe
184 chronic airway disease, which is physiologically distinct but clinically similar to CF and PCD.
185 Our study revealed the prevalence of the *WFDC2* p.C97W variant in the Korean population,
186 suggesting genetic testing for this gene could be beneficial in patients who have respiratory
187 phenotypes resembling PCD or CF.

188 **METHODS**

189 **Study design**

190 This study was approved by the Institutional Review Board of Severance Hospital, Yonsei
191 University Health System (IRB #4-2013-0770 and #4-2024-0647). Written informed consent
192 was obtained from the patients for their participation in this study and the publication of their
193 clinical data. Sixty-four patients with severe bronchiectasis and chronic rhinosinusitis from
194 62 unrelated families were enrolled from both the PCD-like severe bronchiectasis and chronic
195 rhinosinusitis and lung transplantation cohorts at a single tertiary medical center in South
196 Korea. These patients met the European Respiratory Society guidelines for the clinical
197 diagnosis of PCD,¹⁶ which include symptoms such as persistent wet cough, chronic
198 rhinosinusitis, or bronchiectasis. Whole-exome sequencing (WES) or whole-genome
199 sequencing (WGS) was performed to identify potential genetic causes. In-depth genetic
200 analyses were performed on individuals without any potential molecular causes.

201

202 **Analysis of whole exome/genome sequencing data**

203 Genomic DNA was extracted from blood samples of patients clinically suspected of having
204 PCD using a DNeasy Kit (Qiagen, Germany). Whole exome sequencing (WES) was
205 performed using a SureSelect V5 kit (Agilent Technologies, Santa Clara, CA, USA) and an
206 Illumina HiSeq 2500. Raw WES FASTQ files were imported into CLC Genomics Workbench
207 version 9.5.3 for data analysis. Sequenced reads were mapped to the human reference
208 genome, GRCh37/hg19. Variants were detected using the Basic Variant Caller of the CLC
209 Genomics Workbench, with a minimum coverage of 5, a count of 2, and a frequency of 20%.
210 Low-coverage whole genome sequencing (WGS) was performed using a PCR-free DNBSEQ
211 platform (BGI, Beijing, China). Following GATK best practice guidelines, the reads were

212 aligned to the human reference genome GRCh37/hg19 using the Burrows-Wheeler Aligner
213 (BWA-MEM). Duplicates were marked, reads were sorted, and the mapping quality was
214 recalibrated using PICARD-MarkDuplicates and GATK-BQSR. Variant calling of single
215 nucleotide variants (SNVs) and small insertions and deletions (indels) was performed using
216 GATK-HaplotypeCaller, and low-quality variants with a depth of coverage (DP) < 5 and
217 genotype quality (GQ) < 20 were filtered out. Copy Number Variation (CNV) analysis was
218 performed using EXCAVATOR version 2.2 and ExomeDepth (version 1.1.10) with default
219 settings for the WES data. For WGS data, CNVnator
220 (v0.3.2, <https://github.com/abyzovlab/CNVnator>) and GATK-SV
221 (<https://github.com/broadinstitute/gatk-sv>) were used to detect CNV. Mitochondrial variants
222 and transposable element insertion calling were performed using Mutect2 and xTea (v0.1.9;
223 <https://github.com/parklab/xTea>).

224 SNVs and small indels were annotated using Variant Annotation tools in the CLC
225 Workbench or ANNOVAR software. SNVs and small indels were first filtered based on
226 minor allele frequency (MAF), applying a threshold of MAF < 1% according to the Single-
227 Nucleotide Polymorphisms Database (dbSNP), Genome Aggregation Database (gnomAD),
228 and Korean Reference Genome Database (KRGDB); variants that were nonsynonymous or
229 located in splice sites were selected. To evaluate pathogenicity and prioritize the candidate
230 causing variants, *in silico* prediction algorithms, such as MutationTaster, Sorting Tolerant
231 from Intolerant (SIFT), Combined Annotation Dependent Depletion (CADD), Polymorphism
232 Phenotyping v2 (PP2) scores, and public databases including Online Mendelian Inheritance
233 in Man (OMIM) and ClinVar, were used. Interpretation of the variants was performed
234 according to the American College of Medical Genetics and Genomics (ACMG) guidelines.
235 To identify splice site variants, SpliceAI was run on the variants using Ensembl's Variant

236 Effect Predictor (VEP) tool and filtered using a threshold MAF of 1% and delta score
237 threshold of 0.1. Variants were annotated based on their presence in human candidate cis-
238 regulatory elements, as identified using the SCREEN database from the Encyclopedia of
239 DNA Elements (ENCODE) project. Confirmation of the detected variants was performed
240 manually using the Integrative Genomics Viewer (IGV) and through segregation analysis
241 using Sanger sequencing.

242

243 **Structural prediction and clustering**

244 AlphaFold2¹² and ColabFold¹³ were used to construct the *de novo* monomer and dimer
245 WFDC2 structures, respectively. The AlphaFold2-multimer-V2 algorithm was applied
246 without using a template or minimization, using three recycle number parameters in
247 ColabFold. The full-length WT or p.C97W human WFDC2 sequence was used as input. To
248 generate different structural conformations, multiple runs were conducted using different seed
249 values in ColabFold software. A total of 100 different structures were generated for the WT
250 monomer, C97W, homodimer WT, and p. C97W. The monomer and dimer structures were
251 then structurally aligned to perform principal component analysis (PCA) using the bio3d
252 package¹⁷ in R. The *K*-means algorithm was implemented to cluster the structures. The
253 optimal number of clusters suggested by R. ChimeraX¹⁸ was used to visualize protein
254 structures.

255

256 **Cell culture, plasmids, and transfection**

257 Human embryonic kidney (HEK) 293T cells (#CRL-3216, American Type Culture Collection,
258 Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM)
259 supplemented with 10% fetal bovine serum and penicillin (50 IU/mL)/streptomycin

260 (50 µg/mL; Invitrogen, Waltham, MA, USA). The cells were incubated in a 5% CO₂
261 environment at 37°C.

262 Plasmids encoding human *WFDC2* (NM_006103.4) and mouse *Wfdc2*
263 (NM_026323.2, isoform 1 and NM_001374655.1, isoform 2) were purchased from OriGene
264 (Rockville, MD, USA). The coding sequences were amplified by PCR and subcloned into the
265 pcDNA3.4 vector using XbaI and AgeI sites. During PCR, 10xHIS tags were inserted directly
266 into the 3' end in front of the stop codon. Human and mouse *WFDC2* mutants were
267 introduced using the QuikChange mutagenesis method (Agilent Technologies). The pEYFP-
268 ER plasmid was purchased from NovoPro Biosciences (San Diego, CA, USA).

269 HEK293T cells were seeded in 6-well plates the day before transfection. Plasmids
270 were transfected using a PEI-MAX transfection reagent (Polysciences, Warrington, PA, USA)
271 according to the manufacturer's protocol. A total of 0.5 µg of the desired plasmid and 2 µL of
272 PEI-MAX was used for transfection. Cells were used for experiments 24–48 h post-
273 transfection.

274

275 **Immunoblotting**

276 Forty-eight hours after transfection, HEK293T cells were washed twice with phosphate-
277 buffered saline (PBS) and harvested in a lysis buffer containing 150 mM NaCl, 50 mM Tris-
278 HCl (pH 7.4), 1 mM EDTA, 1% Triton X-100, and 1x protease inhibitor cocktail
279 (#04693116001, Sigma-Aldrich, St. Louis, MA, USA). The cells were then briefly sonicated
280 to break the cell membrane and homogenize the sample. Bradford assay was performed to
281 measure the protein concentration at an absorbance of 595 nm. Cell lysates (40–60 µg) were
282 used for analysis.

283 The samples were incubated in 2x sodium dodecyl sulfate (SDS) sample buffer

284 containing dithiothreitol (DTT, 0.02 g/mL) for 30 min at room temperature and subsequently
285 separated using SDS-polyacrylamide gel electrophoresis (PAGE). The separated proteins
286 were transferred onto a nitrocellulose membrane (GE Healthcare, Chicago, IL, USA), which
287 was blotted using suitable primary antibodies and horseradish peroxidase-conjugated
288 secondary antibodies in 5% skimmed milk. Protein bands were visualized using the
289 SuperSignal West Pico kit (Thermo Fisher Scientific) and a blue film (Afga, Belgium). The
290 density of each protein band was quantified using the ImageJ software (<https://imagej.net/ij/>).

291 To detect secreted WFDC2 proteins, transfected cells were incubated in a serum-free
292 medium for 24 h. Culture media were collected and concentrated using Amicon Ultra-4 filters
293 (Millipore, Burlington, MA, USA). The concentrated media was directly heated with 2x SDS
294 sample buffer with DTT and subjected to SDS-PAGE.

295 The following primary and secondary antibodies were used: anti-HIS (#2365, Cell
296 Signaling Technologies, Danvers, MA, USA; 1:1000 dilution), anti-ALDOA (#sc-390733,
297 Santa Cruz Biotechnology, Santa Cruz, TX, USA; 1:000 dilution), HRP Anti-beta Actin
298 antibody (#ab20272, Abcam, Cambridge, UK; 1:2000 dilution), goat anti-rabbit IgG
299 polyclonal antibody (HRP conjugate) (#ADI-SAB-300-J, Farmingdale, Enzo Life Sciences,
300 NY, USA), and goat anti-mouse IgG F(ab')₂ polyclonal antibody (HRP conjugate) (#ADI-
301 SAB-100-J; Enzo Life Sciences; 1:1000 dilution).

302

303 **Immunocytochemistry**

304 Transfected HEK293T cells were cultured on an 18 mm round coverslip. Cells were washed
305 twice with PBS, fixed with 4% paraformaldehyde for 10 min, again washed twice with PBS,
306 and permeabilized with 0.15% Triton X-100 in PBS for 10 min. The cells were washed twice
307 with PBS and incubated with a blocking buffer consisting of 5% donkey serum for 1 h at

308 room temperature. After blocking, the cells were incubated with the appropriate primary
309 antibodies for 1 h at room temperature and washed three times with PBS. Subsequently, the
310 cells were stained with secondary antibodies conjugated to a fluorescent marker for 1 h at
311 room temperature and washed thrice with PBS. The samples were mounted onto glass slides
312 using a mounting medium (Agilent Dako, CA, USA), and images were captured using a
313 confocal microscope (LSM 700, Carl Zeiss, Germany) equipped with a 40× objective lens.

314 The following primary and secondary antibodies were used: anti-HIS (#2365, Cell
315 Signaling Technologies; 1:200 dilution), Alexa Fluor 594 donkey anti-rabbit (#A21207,
316 Invitrogen; 1:400 dilution), Alexa Fluor 647 Phalloidin (#A22287, Invitrogen; 1:400 dilution).

317

318 **Deglycosylation assay**

319 Two methods were used to determine the glycosylation state of WFDC2. After transfection,
320 cells were treated with 2 μM tunicamycin (Sigma-Aldrich) for 20 h. A higher dose or longer
321 incubation time with tunicamycin caused excessive cell death, preventing further analysis.

322 The cells were harvested and subjected to SDS-PAGE, followed by immunoblotting.

323 Transfected cells were denatured in 2x SDS sample buffer containing DTT. Denatured

324 samples were incubated with PNGase F or Endo H (New England Biolabs, Ipswich, MA,

325 USA) according to the manufacturer's protocol. Deglycosylated samples were analyzed using

326 SDS-PAGE and immunoblotting. The shift in protein size was analyzed using both methods.

327 **FUNDING AND SUPPORT**

328 This work was supported by the National Research Foundation (NRF) grants funded by the
329 Korean government (2018R1A5A2025079 and RS-2023-00261905 to H.Y.G. and the Korea
330 Mouse Phenotyping Project RS-2024-00400118 to H.Y.G.). This work was supported by the
331 National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
332 (No. 2022R1A2C1010462 to K.W.K.).

333

334 **COMPETING INTERESTS**

335 The authors declared that no conflicts of interest.

336

337 **ACKNOWLEDGEMENTS**

338 We thank the families that participated in this study. We also thank the Yonsei Advanced
339 Imaging Center and Carl Zeiss Microscope.


340 **REFERENCES**

- 341 1. Davis JD, Wypych TP. Cellular and functional heterogeneity of the airway epithelium. *Mucosal*
342 Immunity 2021;14(5):978-990. DOI: 10.1038/s41385-020-00370-7.
- 343 2. Hiemstra PS, McCray PB, Jr., Bals R. The innate immune function of airway epithelial cells in
344 inflammatory lung disease. *Eur Respir J* 2015;45(4):1150-62. DOI:
345 10.1183/09031936.00141514.
- 346 3. Lee S-N, Yoon J-H. The Role of Proprotein Convertases in Upper Airway Remodeling.
347 *Molecules and Cells* 2022;45(6):353-361. DOI: <https://doi.org/10.14348/molcells.2022.0019>.
- 348 4. Jevnikar Z, Ostling J, Ax E, et al. Epithelial IL-6 trans-signaling defines a new asthma
349 phenotype with increased airway inflammation. *J Allergy Clin Immunol* 2019;143(2):577-590.
350 DOI: 10.1016/j.jaci.2018.05.026.
- 351 5. Vieira Braga FA, Kar G, Berg M, et al. A cellular census of human lungs identifies novel cell
352 states in health and in asthma. *Nat Med* 2019;25(7):1153-1163. DOI: 10.1038/s41591-019-
353 0468-5.
- 354 6. De Rose V, Molloy K, Gohy S, Pilette C, Greene CM. Airway Epithelium Dysfunction in Cystic
355 Fibrosis and COPD. *Mediators Inflamm* 2018;2018:1309746. DOI: 10.1155/2018/1309746.
- 356 7. Zoso A, Sofoluwe A, Bacchetta M, Chanson M. Transcriptomic profile of cystic fibrosis airway
357 epithelial cells undergoing repair. *Sci Data* 2019;6(1):240. DOI: 10.1038/s41597-019-0256-6.
- 358 8. Whitsett JA. Airway Epithelial Differentiation and Mucociliary Clearance. *Ann Am Thorac Soc*
359 2018;15(Suppl 3):S143-S148. DOI: 10.1513/AnnalsATS.201802-128AW.
- 360 9. Leigh MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles MR. Primary Ciliary
361 Dyskinesia (PCD): A genetic disorder of motile cilia. *Transl Sci Rare Dis* 2019;4(1-2):51-75.
362 DOI: 10.3233/TRD-190036.
- 363 10. Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary Clearance. *Cold Spring Harb*
364 *Perspect Biol* 2017;9(4). DOI: 10.1101/cshperspect.a028241.
- 365 11. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific
366 haplotype structure and linking correlated alleles of possible functional variants.
367 *Bioinformatics* 2015;31(21):3555-7. DOI: 10.1093/bioinformatics/btv402.
- 368 12. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with
369 AlphaFold. *Nature* 2021;596(7873):583-589. DOI: 10.1038/s41586-021-03819-2.
- 370 13. Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making
371 protein folding accessible to all. *Nat Methods* 2022;19(6):679-682. DOI: 10.1038/s41592-022-
372 01488-1.
- 373 14. Bingle L, Ames H, Williams D, et al. Expression and function of murine WFDC2 in the
374 respiratory tract. *bioRxiv* 2020:2020.05.05.079293. DOI: 10.1101/2020.05.05.079293.
- 375 15. Dougherty GW, Ostrowski LE, Nöthe-Menchen T, et al. Recessively Inherited Deficiency of

- 376 Secreted WFDC2 (HE4) Causes Nasal Polyposis and Bronchiectasis. *Am J Respir Crit Care*
377 *Med* 2024;210(1):63-76. (In eng). DOI: 10.1164/rccm.202308-1370OC.
- 378 16. Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the
379 diagnosis of primary ciliary dyskinesia. *Eur Respir J* 2017;49(1). DOI:
380 10.1183/13993003.01090-2016.
- 381 17. Grant BJ, Rodrigues AP, ElSawy KM, McCammon JA, Caves LS. Bio3d: an R package for
382 the comparative analysis of protein structures. *Bioinformatics* 2006;22(21):2695-6. DOI:
383 10.1093/bioinformatics/btl461.
- 384 18. Pettersen EF, Goddard TD, Huang CC, et al. UCSF ChimeraX: Structure visualization for
385 researchers, educators, and developers. *Protein Sci* 2021;30(1):70-82. DOI:
386 10.1002/pro.3943.
- 387 19. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2--a multiple
388 sequence alignment editor and analysis workbench. *Bioinformatics* 2009;25(9):1189-91. DOI:
389 10.1093/bioinformatics/btp033.
- 390

391


FIGURE LEGENDS



392

393 **Fig. 1. Identification of a homozygous variant in *WFDC2* in families with severe**
394 **bronchiectasis and chronic rhinosinusitis.**

395 (A, B) Summary and result of WES/WGS analysis to elucidate the causal variants in patients
396 with severe bronchiectasis and chronic rhinosinusitis. Five families had a homozygous
397 variant in *WFDC2*, which was the c.291C>G substitution resulting in the amino acid change
398 p.Cys97Trp. (C) Pedigree of five families with the c.291C>G *WFDC2* variant. The probands
399 are indicated using arrows. (D) Sanger sequencing result of c.291C>G *WFDC2* variant
400 representing individuals from three families. The altered amino acid is written in red. WES,
401 Whole exome sequencing; WGS, whole genome sequencing.




402

403 **Fig. 2. Clinical manifestation of individuals with bi-allelic *WFDC2* variant.**

404 (A) Radiologic findings of patients with progressive destructive lung diseases requiring lung
405 transplantation. Left panels display extensive cystic/cylindrical bronchiectasis with bronchial
406 wall thickening, fibrosis, and air trappings. Additionally, peribronchial and centrilobular

20

407 nodules are present, along with consolidations and bronchial mucoid stagnations (P1969-22),
408 parenchymal destruction in the right upper lobe (P2678-22), and volume loss in both upper
409 lobes (P2678-22). Right panels demonstrate much improved radiologic findings after lung
410 transplantation, with no evidence of bronchiectasis, bronchial wall thickening, fibrosis, or air
411 trappings. (B) P5-21 and P5-22 showed diffuse bronchiectasis with mucoid impactions and
412 centrilobular nodules in both lungs. (C) Nasal endoscopic images showing polyposis and
413 thick mucoid discharge. (D) Lung histology H&E staining images acquired during
414 transplantation. Pathologic signs showed bronchiectasis with peribronchial inflammation and
415 fibrosis (P1969-21) and bronchiectasis and bronchiolectasis with peribronchial inflammation
416 and fibrosis (P2678-21). In (D), the scale bars are 50 μm . H&E, hematoxylin and eosin.



417

418 **Fig. 3. Molecular mechanism of WFDC2 p.C97W mutant.**

419 (A) Overall structure of the WFDC2 protein. Two WAP domains and the disulfide bond-
 420 forming cysteines are shown. C97 forms a disulfide bond with C109. (B) Multiple sequence
 421 alignment of human WFDC2 against its orthologs from five different vertebrate species was
 422 performed using Jalview.¹⁹ The mutated amino acid residue (C97) and the disulfide bond-
 423 forming cysteine residue with C97 (C109) are indicated. (C) Monomer and homo-dimer
 424 structure prediction of WFDC2 WT and p.C97W mutant by AlphaFold2.^{12,13} (D) Western blot
 425 analysis of WT and p.C97W mutant WFDC2 proteins in both the lysates and secreted media
 426 of HEK293T cells overexpressing the proteins. In (D), data are presented in mean \pm standard
 427 error of the mean. In (D), a two-way Student's t-test was used to calculate the p-value, and a
 428 p-value < 0.05 was considered significant. *, $p < 0.05$; ****, $p < 0.0001$.

Table 1. Clinical characteristics of the patients

Patient	P1946-21	P1969-21	P2678-21	P2783-21	P5-21	P5-22
Age at confirmation of <i>WFDC2</i> mutation, years	31-35	36-40	46-50	31-35	21-25	21-25
Sex	Male	Female	Female	Female	Male	Male
Bronchiectasis	N/A	Yes	Yes	Yes	Yes	Yes
<i>Pseudomonas aeruginosa</i> infection	N/A	Yes	Yes	Yes	N/A	N/A
Chronic rhinosinusitis	Yes	Yes	Yes	Yes	Yes	Yes
Nasal polyposis	No	No	No	Yes	Yes	Yes
Age at transferred, years	26-30	31-35	36-40	16-20	21-25	21-25
Lung Transplantation (age, years)	No	Yes (36-40)	Yes (41-45)	Yes (21-25)	No	No
Medical history of siblings	Deceased due to pneumonia	No	Reduced lung function	No	Sibling of P5-22	Sibling of P5-21
Pulmonary function *						
FEV ₁ (% pred)	N/A	29	21	22	85	71
FEV ₁ (L)	N/A	0.86	0.56	0.69	3.55	3.14
FEV ₁ /FVC (%)	N/A	44	49	44	81	81
DLCO		37				

429 N/A, data not available

430 * Pulmonary function tests were performed just before lung transplantation for P1969-21, P2678-21, and P2783-21, and most recently for P5-
 431 1 and P5-2.